700
Participants
Start Date
September 30, 2013
Primary Completion Date
November 30, 2014
Study Completion Date
November 30, 2014
Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Monovalent influenza A/H7N9 virus vaccine for intramuscular use is a sterile, clear and slightly opalescent suspension. sanofi A/H7N9 antigen. Group 1 receives 3.75mcg A/H7N9 IM on days 1 and 21, Group 2 receives 7.5 mcg IM on days 1 and 21, Group 3, 4, 5, \& 6 receives 15 mcg IM on days 1 and 21, and Group 7 receives 45 mcg IM on days 1 and 21.
MF59
MF59 adjuvant is an oil-in-water emulsion composed of a small amount of squalene administered with different dosages. Group 1, 2 \& 3 receives 0.7 ml of MF59 Intramuscularly (IM) on days 0 and 21. Group 4 receives MF59 on day 0, Group 5 receives MF59 on Day 21.
Emory Vaccine Center - The Hope Clinic, Decatur
University of Iowa - Infectious Disease Clinic, Iowa City
Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati
University of Texas Medical Branch - Pediatrics - Infectious Diseases and Immunology - Galveston, Galveston
National Institute of Allergy and Infectious Diseases (NIAID)
NIH